These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19132200)

  • 1. Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis.
    Shorr AF; Williams MD
    Thromb Haemost; 2009 Jan; 101(1):139-44. PubMed ID: 19132200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer.
    Vedovati MC; Becattini C; Rondelli F; Boncompagni M; Camporese G; Balzarotti R; Mariani E; Flamini O; Pucciarelli S; Donini A; Agnelli G
    Ann Surg; 2014 Apr; 259(4):665-9. PubMed ID: 24253138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).
    Levi M; Levy M; Williams MD; Douglas I; Artigas A; Antonelli M; Wyncoll D; Janes J; Booth FV; Wang D; Sundin DP; Macias WL;
    Am J Respir Crit Care Med; 2007 Sep; 176(5):483-90. PubMed ID: 17556722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous thromboembolism in critical illness in a community intensive care unit.
    Muscedere JG; Heyland DK; Cook D
    J Crit Care; 2007 Dec; 22(4):285-9. PubMed ID: 18086398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism prophylaxis in the critically ill: a point prevalence survey of current practice in Australian and New Zealand intensive care units.
    Robertson MS; Nichol AD; Higgins AM; Bailey MJ; Presneill JJ; Cooper DJ; Webb SA; McArthur C; MacIsaac CM; ;
    Crit Care Resusc; 2010 Mar; 12(1):9-15. PubMed ID: 20196708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis against venous thromboembolism in hospitalized medically ill patients.
    Pendergraft T; Liu X; Edelsberg J; Phatak H; Vera-Llonch M; Liu LZ; Oster G
    Circ Cardiovasc Qual Outcomes; 2013 Jan; 6(1):75-82. PubMed ID: 23300270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venous and arterial thromboembolism in severe sepsis.
    Levine RL; LeClerc JR; Bailey JE; Monberg MJ; Sarwat S
    Thromb Haemost; 2008 May; 99(5):892-8. PubMed ID: 18449418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of chemical thromboprophylaxis in critically ill medical and surgical patients with sepsis.
    Hanify JM; Dupree LH; Johnson DW; Ferreira JA
    J Crit Care; 2017 Feb; 37():206-210. PubMed ID: 27969572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboprophylaxis using combined intermittent pneumatic compression and pharmacologic prophylaxis versus pharmacologic prophylaxis alone in critically ill patients: study protocol for a randomized controlled trial.
    Arabi YM; Alsolamy S; Al-Dawood A; Al-Omari A; Al-Hameed F; Burns KE; Almaani M; Lababidi H; Al Bshabshe A; Mehta S; Al-Aithan AM; Mandourah Y; Almekhlafi G; Finfer S; Abdukahil SA; Afesh LY; Dbsawy M; Sadat M
    Trials; 2016 Aug; 17(1):390. PubMed ID: 27488380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism prophylaxis in hospitalized heart failure patients.
    Jois-Bilowich P; Michota F; Bartholomew JR; Glauser J; Diercks D; Weber J; Fonarow GC; Emerman CL; Peacock WF;
    J Card Fail; 2008 Mar; 14(2):127-32. PubMed ID: 18325459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock.
    Lai PS; Matteau A; Iddriss A; Hawes JC; Ranieri V; Thompson BT
    Minerva Anestesiol; 2013 Jan; 79(1):33-43. PubMed ID: 23174922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current treatment practices of venous thromboembolism in children admitted to pediatric intensive care units.
    Hanson SJ; Lawson KA; Brown AM; Christie LM; McArthur JA; Totapally B; Higgerson RA
    Paediatr Anaesth; 2011 Oct; 21(10):1052-7. PubMed ID: 21767328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
    Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
    J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Prophylactic Heparin Dosage Strategies and Risk Factors for Venous Thromboembolism in the Critically Ill Patient.
    Reynolds PM; Van Matre ET; Wright GC; McQueen RB; Burnham EL; Ho PJM; Moss M; Vandivier RW; Kiser TH;
    Pharmacotherapy; 2019 Mar; 39(3):232-241. PubMed ID: 30592541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thromboembolism prophylaxis and clinical consequences in medically ill patients.
    Baser O; Liu X; Phatak H; Wang L; Mardekian J; Kawabata H; Petersel D; Hamilton M; Ramacciotti E
    Am J Ther; 2013; 20(2):132-42. PubMed ID: 23466619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey.
    Bergmann JF; Cohen AT; Tapson VF; Goldhaber SZ; Kakkar AK; Deslandes B; Huang W; Anderson FA;
    Thromb Haemost; 2010 Apr; 103(4):736-48. PubMed ID: 20135072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
    Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Practice of pharmaceutical thrombosis prophylaxis and anticoagulation in patients with sepsis and pre-existing anticoagulation or heparin-induced type II thrombocytopenia-Results of a nationwide survey in German intensive care units].
    Schmoch T; Brenner T; Becker-Pennrich A; Hinske LC; Weigand MA; Briegel J; Möhnle P;
    Anaesthesist; 2022 Mar; 71(3):193-200. PubMed ID: 34351433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.